This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per share. This was partly due to its softer quarterly results and may have ...

Moderna's Q1 2022 financial performance was better than expected, but MRNA didn't raise full-year 2022 guidance. See if MRNA stock is a buy, sell, or hold.

Moderna (MRNA-1.32%), a leader in the field of messenger RNA (mRNA)-based vaccines and therapeutics, is a prime example. The company's stock price skyrocketed in 2021, thanks to the strong sales ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

A Look at Moderna's Recent Stock Price Performance Over the past month, the stock has seen a decline of 14.2% in its value, whereas the Zacks S&P 500 composite has posted a decrease of 0.5%.